Post-Bariatric Hypoglycemia Clinical Trial
Official title:
Role of Nutrient Transit and Incretin Hormones in Hyperinsulinemic Hypoglycemia
NCT number | NCT04615546 |
Other study ID # | 52254 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 6, 2020 |
Est. completion date | June 2024 |
Verified date | August 2023 |
Source | Stanford University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Severe hypoglycemia (low blood sugar)after gastric bypass surgery is an increasingly recognized condition, characterized by symptoms of hypoglycemia after eating and inappropriately elevated insulin concentrations that occur at the time of hypoglycemia. Severe hypoglycemia can be dangerous and debilitating and can also impact cognitive function. At the moment no medical therapies have been developed for this disorder. Determining why some but not other patients develop this condition would allow for improved prediction, prevention, and treatment approaches. The purpose of the study is to understand the physiological changes observed in those patients who undergo gastric bypass and develop symptomatic hypoglycemia.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | June 2024 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male or female patients 18-70 years of age - Post-bariatric surgery more than 6 months prior to signing the informed consent (not required for non-surgical controls) - Documented history of hyperinsulinemic hypoglycemia (not required for post-bariatric and non-surgical controls) Exclusion Criteria: - Patients currently using sulfonylureas or other medications that may interfere with glucose metabolism within 5 half-lives of drug. - Participation in any clinical investigation within 4 weeks prior to dosing - History of or current insulinoma - Active infection or significant acute illness within 2 weeks prior to dosing - Female patients who are pregnant or lactating - Women of childbearing potential and not utilizing effective contraceptive methods - Inadequate end organ function as defined by: Serum creatinine >2.0 mg/dL, alanine transaminase (ALT) and aspartate aminotransferase (AST) > 2 x Upper Normal Limit - Allergy to test meal or medications used in the study |
Country | Name | City | State |
---|---|---|---|
United States | Stanford University School of Medicine | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Stanford University | American Diabetes Association |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Steady state plasma glucose (SSPG) as a measure of insulin sensitivity | This endpoint applies to the In-Clinic Phase cohorts: Post-Bariatric Hypoglycemia, Surgical Controls, Non-Surgical Controls. This is a one day in-person appointment lasting approximately 6 hours. | Baseline 4-hour SSPG | |
Primary | Rate of gastric emptying | This endpoint applies to the In-Clinic Phase cohorts: Post-Bariatric Hypoglycemia, Surgical Controls, Non-Surgical Controls. This is an in-person appointment lasting approximately 5 hours. | Baseline 4-hour scintigraphy procedure | |
Primary | Concentration of Glucagon-Like peptide 1 secretion augmentation of insulin secretion rate | This endpoint applies to the In-Clinic Phase cohorts: Post-Bariatric Hypoglycemia, Surgical Controls, Non-Surgical Controls. The blood collected from the SSPG will be stored and analyzed for the concentration of GLP-1 at multiple timepoints. | Baseline 4-hour graded-glucose infusion | |
Primary | Rate of clinically important hypoglycemia (Level 2 hypoglycemia, <54 mg/dL) | This endpoint applies to Remote Phase participants | 40 days | |
Primary | Percent time in clinically important hypoglycemia (Level 2 hypoglycemia, <54 mg/dL) | This endpoint applies to Remote Phase participants | 40 days | |
Primary | Rate of arrhythmia during hypoglycemia | This endpoint applies to Remote Phase participants | 10 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03255629 -
Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT05928390 -
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
|
Phase 2 | |
Completed |
NCT05560789 -
The Effect of Physical Activity in Individuals With Post-bariatric Hypoglycemia
|
N/A |